Targeted Agents for Wall Imaging

  • Emily A. Waters
  • Thomas J. Meade


MRI is an increasingly important diagnostic tool for cardiovascular pathology, with the ability to assess ventricular wall motion, myocardial perfusion and viability, coronary artery disease, and the function of the cardiac valves. However, MR imaging is primarily used for diagnosis of functional abnormalities, which do not occur until relatively late in disease processes (often after irreversible tissue damage has occurred). Molecular imaging allows observation of disease processes as they occur, before functional abnormalities become apparent. Not only does it hold great promise for early and more accurate diagnoses but it also enables direct observation of therapeutic efficacy in individual patients, allowing optimization of the treatment regimen for each person. Furthermore, by allowing direct observation of physiological processes at the molecular level, molecular imaging enables longitudinal study of disease biochemistry.


Contrast Agent Atherosclerotic Plaque Molecular Imaging Aortic Wall Iron Oxide Nanoparticles 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Sinusas AJ, Bengel F, Nahrendorf M, et al. Multimodality cardiovascular molecular imaging, part I. Circ Cardiovasc Imaging. 2008 2008;1:244–256.Google Scholar
  2. 2.
    Thim T, Hagensen M, Bentzon J, Falk E. From vulnerable plaque to atherothrombosis. J. Intern. Med. 2008;263:506–516.PubMedCrossRefGoogle Scholar
  3. 3.
    Sanz J, Fayad ZA. Imaging of atherosclerotic cardiovascular disease. Nature. 2008;451:953–957.PubMedCrossRefGoogle Scholar
  4. 4.
    Kelly K, Allport J, Tsourkas A, Shinde-Patil V, Josephson L, Weissleder R. Detection of vascular adhesion molecule-1 expression using a novel multimodal nanoparticle. Circ Res. 2005;96:327–336.PubMedCrossRefGoogle Scholar
  5. 5.
    Ruehm S, Corot C, Vogt P, Kolb S, Debatin J. Magnetic resonance imaging of atherosclerotic plaque with ultrasmall superparamagnetic particles of iron oxide in hyperlipidemic rabbits. Circulation. 2001;103:415–422.PubMedGoogle Scholar
  6. 6.
    Von zur Muhlen C, Von Elverfeldt D, Moeller J, et al. Magnetic resonance imaging contrast agent targeted toward activated platelets allows in vivo detection of thrombosis and monitoring of thrombolysis. Circulation. 2008;118(3):258–267.Google Scholar
  7. 7.
    Frias J, Ma Y, Williams K, Fayad Z, Fisher E. Properties of a versatile nanoparticle platform contrast agent to image and characterize atherosclerotic plaques by magnetic resonance imaging. Nano Lett. 2006;6:2220–2224.PubMedCrossRefGoogle Scholar
  8. 8.
    Briley-Saebo KC, Shaw PX, Mulder WJ, et al. Targeted molecular probes for imaging atherosclerotic lesions with magnetic resonance using antibodies that recognize oxidation-specific epitopes. Circulation. 2008;117:3206–3215.PubMedCrossRefGoogle Scholar
  9. 9.
    Mulder W, Strijkers G, Briley-Saboe K, et al. Molecular imaging of macrophages in atherosclerotic plaques using bimodal PEG-micelles. Magn Reson Med. 2007;58:1164–1170.PubMedCrossRefGoogle Scholar
  10. 10.
    Beilvert A, Cormode D, Chaubet F, et al. Tyrosine polyethylene glycol (PEG)-micelle magnetic resonance contrast agent for the detection of lipid rich areas in atherosclerotic plaque. Magn Reson Med. 2009;62:1195–1201.PubMedCrossRefGoogle Scholar
  11. 11.
    Winter P, Morawski A, Caruthers S, et al. Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. Circulation. 2003;108:2270–2274.PubMedCrossRefGoogle Scholar
  12. 12.
    Morawski AM, Winter PM, Yu X, et al. Quantitative “magnetic resonance immunohistochemistry” with ligand-targeted (19)F nanoparticles. Magn Reson Med. 2004;52:1255–1262.PubMedCrossRefGoogle Scholar
  13. 13.
    Tang TY, Muller KH, Graves MJ, et al. Iron oxide particles for atheroma imaging. Arterioscler Thromb Vasc Biol. 2009;29:1001–1008.PubMedCrossRefGoogle Scholar
  14. 14.
    McAteer M, Schneider J, Ali Z, et al. Magnetic resonance imaging of endothelial adhesion molecules in mouse atherosclerosis using dual-targeted microparticles of iron oxide. Arterioscler Thromb Vasc Biol. 2008;28:77–83.PubMedCrossRefGoogle Scholar
  15. 15.
    Botnar R, Perez A, Witte S, et al. In vivo molecular imaging of acute and subacute thrombosis using a fibrin-binding magnetic resonance imaging contrast agent. Circulation. 2004;109:2023–2029.PubMedCrossRefGoogle Scholar
  16. 16.
    Aime S, Castelli DD, Crich SG, Gianolio E, Terreno E. Pushing the sensitivity envelope of lanthanide-based magnetic resonance imaging (MRI) contrast agents for molecular imaging applications. Acc Chem Res. 2009;42:822–831.PubMedCrossRefGoogle Scholar
  17. 17.
    Winter PM, Caruthers SD, Yu X, et al. Improved molecular imaging contrast agent for detection of human thrombus. Magn Reson Med. 2003;50:411–416.PubMedCrossRefGoogle Scholar
  18. 18.
    Meding J, Urich M, Licha K, et al. Magnetic resonance imaging of atherosclerosis by targeting extracellular matrix deposition with Gadofluorine M. NMR Biomed. 2007;2:120–129.Google Scholar
  19. 19.
    Lusis AJ. Atherosclerosis. Nature. 2000;407:233–241.PubMedCrossRefGoogle Scholar
  20. 20.
    Nahrendorf M, Sosnovik DE, French BA, et al. Multimodality cardiovascular molecular imaging, part II. Circ Cardiovasc Imaging. 2009;2:56–70.PubMedCrossRefGoogle Scholar
  21. 21.
    Lancelot E, Amirbekian V, Brigger I, et al. Evaluation of matrix metalloproteinases in atherosclerosis using a novel noninvasive imaging approach. Arterioscler Thromb Vasc Biol. 2008;28:425–432.PubMedCrossRefGoogle Scholar
  22. 22.
    Alsaid H, De Souza G, Bourdillon M, et al. Biomimetic MRI Contrast agent for imaging of inflammation in atherosclerotic plaque of ApoE−/− mice: a pilot study. Invest Radiol. 2009;44:151–158.PubMedCrossRefGoogle Scholar
  23. 23.
    Chaubet F, Bertholon I, Serfaty J, et al. A new macromolecular paramagnetic MR contrast agent binds to activated human platelets. Contrast Media Mol Imaging. 2007;2:178–188.PubMedCrossRefGoogle Scholar
  24. 24.
    Slevin M, Kumar P, Wang Q, et al. New VEGF antagonists as possible therapeutic agents in vascular disease. Expert Opin Invest Drugs. 2008;17:1301–1314.CrossRefGoogle Scholar
  25. 25.
    Winter P, Caruthers S, Zhang H, Williams T, Wickline S, Lanza G. Antiangiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosis. JACC Cardiovasc Imaging. 2008;1:624–634.PubMedCrossRefGoogle Scholar
  26. 26.
    Major JL, Meade TJ. Bioresponsive, cell-penetrating, and multimeric MR contrast agents. Acc Chem Res. 2009;42:893–903.PubMedCrossRefGoogle Scholar
  27. 27.
    Rodriguez E, Nilges M, Weissleder R, Chen J. Activatable magnetic resonance imaging agents for myeloperoxidase sensing: mechanism of activation, stability, and toxicity. J Am Chem Soc. 2009;132:168–177.CrossRefGoogle Scholar
  28. 28.
    Ronald J, Chen J, Chen Y, et al. Enzyme-sensitive magnetic resonance imaging targeting myeloperoxidase identifies active inflammation in experimental rabbit atherosclerotic plaques. Circulation. 2009;120:592–599.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of ChemistryNorthwestern UniversityEvanstonUSA

Personalised recommendations